Tick-borne encephalitis vaccines: past and present.
Vaccines to protect against tick-borne encephalitis (TBE) are produced by two manufacturers and are widely used in European and Asian countries, where TBE virus is endemic. General trends in vaccine development during recent decades and extensive postmarketing experience resulted in several modifications to their formulations and practical implications for use. Modifications were made to the production process, such as the change of the virus master bank from mouse brain to primary cells; to the excipients, especially the stabilizers and preservative; and to include formulations for children. Additionally, a rapid vaccination schedule has been developed for persons who require a fast onset of protection. Recent data from clinical studies and postmarketing surveillance indicate that both vaccines are safe, efficacious and interchangeable. Further (major) changes to formulation or alternative targets for vaccine development are not anticipated in the next 5 years. Recent serologic studies indicate that the persistence of protective immunity was longer than expected. Thus, recommendations for prolongation of TBE booster intervals have been made in several European countries, and a harmonization for booster recommendations is predicted within the European Union. Based on epidemiologic trends, the use of TBE vaccines will continue to increase in all age groups, including children.
Zent
Olaf
O
Chiron Vaccines, Clinical Research and Medical Affairs, Chiron Behring GmbH & Co KG, Emil-von-Behring Str. 76, 35041 Marburg, Germany. olaf_zent@chiron.com
Bröker
Michael
M
D000367:Age Factors; D002986:Clinical Trials as Topic; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D004675:Encephalitis, Tick-Borne / Q000517:prevention & control*; D049673:History, 20th Century; D006801:Humans; D007115:Immunization Schedule; D011358:Product Surveillance, Postmarketing; D014611:Vaccination; D014765:Viral Vaccines / Q000266:history
D014765:Viral Vaccines